Trial Profile

A phase 1 trial of NKTR-0165

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NKTR 0165 (Primary)
Indications Autoimmune disorders
Focus Adverse reactions; First in man

Most Recent Events

12 Mar 2025 According to a Nektar Therapeutics media release, company plan to submit the IND for NKTR-0165 in the second half of this year."
08 Aug 2024 According to a Nektar Therapeutics media release, company is preparing for an IND submission in the middle of 2025.
12 Jun 2024 According to a Nektar Therapeutics media release, IND-Enabling Studies Underway for NKTR-0165 with First-in-Human Studies Planned in First Half of 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com